how is hers still selling semaglutide Deadline to stop cheaper versions of GLP-1 medications nears Hims & Hers Super Bowl

In February 2026, the FDA publicly announced its intent to take action targeting mass-marketed, non-FDA-approved compounded GLP1 products, emphasizing that promotional claims implying equivalence to FDAapproved drugs can trigger enforcement risk

Patent-pending XOSM Technology boosts formula performance with encapsulated antioxidants ectoin, vitamin C and astaxanthin-rich micro-algae while protecting and nourishing skins barrier, for a visibly firm and radiant, younger-looking complexion

Results In total, 9795 patients in the GLP-1 RAs group (302 with HF

Once a relatively obscure class of drugs prescribed for people with diabetes, GLP-1s have now shown an impressive ability to treat obesity, which affects...

GLP-1 (glukagonin kaltainen peptidi-1) on suolistossa luonnostaan muodostuva hormoni, jolla on trke rooli ruokahalun stelyss, insuliinisignaloinnissa ja verensokeritasapainossa

Leading Players in the GLP-1 Market Novo Nordisk 38.72% Ozempic Wegovy Rybelsus Eli Lilly 28.41% Mounjaro Zepbound Sanofi 8.76% 4 AstraZeneca 6.62% 5 GSK 4.95% 6 Regeneron 3.27% 7 Pfizer 2.61% 8 Amgen 1.98% 9 Sun Pharma 1.52% Boehringer Ingelheim 1.24% Together, Novo Nordisk and Eli Lilly account for more than 67% of the market, highlighting the intense competition between the two companies that currently lead the obesity and diabetes treatment revolution